HARBIN, China, April 29 /Xinhua-PRNewswire-FirstCall/ -- Renhuang
Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" or "the Company"), a
leading pharmaceutical company in the People's Republic of China ("PRC"),
today announced its successful participation in the 103rd China Import and
Export Fair in Guangzhou, China from April 15th to April 30th 2008.
With more than a fifty-year history, the China Import and Export Fair is
one of the most well attended trade shows in China, and it boasts the widest
array of products from around the globe. This year, there were more than
300,000 people attending the trade show, representing industries as diverse as
clothing, chemicals, computers, auto, foods, electronics, energy, appliances,
drinks, pharmaceuticals and machinery. Among the 300,000 attendees, about
200,000 came from 213 countries outside of China. The China Import and Export
Fair is considered by many businesses to be the most effective exhibition in
China, as it generates a high volume of transactions.
At the trade show, Renhuang presented its leading branded drugs
Acanthopanax (Siberian Ginseng) and Tianma Headache Relief Pills.
Acanthopanax,
extracted from natural plants for the treatment of sleep disorders and
depression, is highly popular with the overseas distributors. The Company's
booth attracted more than 1,500 visitors. Among them, over 500 distributors
have expressed strong interest in licensing and distributing the Company's
products. The Company is in discussion with about 100 distributors as
potential distribution partners and to date has already signed three letters
of intent for distribution collaborations.
"We are excited that our products were so highly regarded at the China
Import and Export Fair. This speaks to our strong brand name recognition and
strong worldwide customer demand. We intend to continue with our strategy of
developing high quality products and expanding our presence in the overseas
market," said Mr. Shao-ming Li, Chairman and CEO of Renhaung Pharmaceuticals,
Inc.
About Renhuang Pharmaceuticals, Inc.
Founded in 1996, Renhuang Pharmaceuticals, Inc, produces Western,
traditional Chinese medicines (TCM), and branded pharmaceuticals, using its
GMP-certified facilities in China. The Company's GMP-certified manufacturing
facilities, containing cutting-edge technologies and advance equipment, are
capable of producing a many as 200 types of pharmaceuticals. Additionally,
Renhuang distributes raw materials and finished pharmaceuticals using its
broad distribution channels and third party distributors throughout China. The
Company's distribution network includes over 3,000 sales representatives in 70
sales centers across 24 districts, covering over 50% of the greater China. The
Company also exports its products to Russia and Southeast Asia. For more
information, visit http://www.renhuang.com .
Safe Harbor Statement
This press release contains certain statements that may include
'forward-looking statements' as defined in the Securities Act of 1933, and the
Securities Exchange Act of 1934. All statements, other than statements of
historical facts, included herein are 'forward-looking statements'. Although
the Company believes that the expectations reflected in these forward-looking
statements are reasonable, they do involve assumptions, risks and
uncertainties, and these expectations may prove to be incorrect. You should
not place undue reliance on these forward-looking statements, which speak only
as of the date of this press release.
The Company's actual results could differ materially from those
anticipated in these forward-looking statements as a result of a variety of
factors, including those discussed in the Company's periodic reports that are
filed with and available from the Securities and Exchange Commission. All
forward-looking statements attributable to the Company or persons acting on
its behalf are expressly qualified in their entirety by these factors. Other
than as required under the securities laws, the Company does not assume a duty
to update these forward-looking statements.
For more information, please contact:
Renhuang Pharmaceuticals, Inc.
Ms. Shuang Tan, IR Contact
Tel: +86-451-5392-5461
Email: ir@renhuang.com
CCG Elite Investor Relations Inc.
Mr. Crocker Coulson, President
Tel: +1-646-213-1915 (New York)
Email: crocker.coulson@ccgir.com
SOURCE Renhuang Pharmaceuticals, Inc.
Ms. Shuang Tan, IR Contact of Renhuang Pharmaceuticals, Inc.,
+86-451-5392-5461, or ir@renhuang.com; or Mr. Crocker Coulson, President of
CCG Elite Investor Relations Inc.,+1-646-213-1915 (New York), or
crocker.coulson@ccgir.com
